System Development Lifecycle Sample Clauses

System Development Lifecycle. AGENCY2 shall manage the information system using an SDLC that incorporates information security considerations and integrates the agency information security risk management process into SDLC activities. AGENCY2 shall define and document information security roles and responsibilities throughout the SDLC and identify individuals having information security roles and responsibilities
AutoNDA by SimpleDocs
System Development Lifecycle. Manage the Provider Systems incorporating information security and privacy considerations; define and document information security and privacy roles and responsibilities throughout the system development life cycle; and identify individuals having information security and privacy roles and responsibilities; and integrate the organizational information security and privacy risk management process into system development life cycle activities.
System Development Lifecycle. Callback Some batch processes require callback in the event that a batch process does not run to completion and requires attention to resolve. Unless otherwise noted, WaTech monitors these systems and if intervention is required, will execute the appropriate callback as outlined in their service agreements. The following systems require callback: BPS: L&I’s Operations supports BPS system processing M-F 6am-3pm. Otherwise, WaTech monitors processing. EAS: System 14, System 15, System 22, System 21, System RR, and System RA – Xxx Xxxxxx (NEWW235), Xxxx Xxxxxxxxxx (SCHI235) MIPS: System 33, System 34, and any other MIPS-related processes – Xxxxxxx Xxxxxx (TURS235) Developer Preparedness Add stuff here Approval/Acceptance Agreement Review Process An initial review of this agreement will be conducted three months from the effective date with all parties. Subsequent reviews will be performed annually. A representative of any of the parties may initiate a review at any time by submitting a written request for review of the Agreement to the Service Desk representative, who will arrange a meeting of the parties. In the absence of the completion of a review, the current Agreement will remain in effect. The Service Desk representative will incorporate revisions into the Agreement if all parties agree to the proposed changes. Initial Review: October 2016 Next Review: October 2017 Term and Review Cycle This Agreement is valid from March 1, 2017 and remains in effect until revoked or modified. OLA Change Review Triggers When one of the following occurs or is anticipated contact Information Services Applications & Data Management Office to initiate the review process: Any change to availability of any component (see Technology above). The addition or removal of a role, or changes to role definitions. Technical or Business Owner changes Completion or changes to the service including addition and removal of components and dependent systems/technology. Consistent or regular outages causing business interruption. Agreement Acceptance The project phase for MPN will end on June 30, 2013. At this point, any changes to the MPN applications will need to be done through the appropriate IS Core Teams. At project closure, all knowledge transfer will be completed and TFS code-base, artifacts, and environments will be turned over to the appropriate IS Core teams.

Related to System Development Lifecycle

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

Time is Money Join Law Insider Premium to draft better contracts faster.